Straits Times Index
3,240.58 +49.87 (+1.56%) S&P 500
3,901.36 +0.57 (+0.01%) Dow
31,261.90 +8.80 (+0.03%) Nasdaq
11,354.62 -33.88 (-0.30%) BTC-USD
30,008.17 +549.51 (+1.87%) CMC Crypto 200
650.34 -23.03 (-3.42%)
TAK Jan 2023 17.000 call
| Previous close | 0.3500 |
| Open | 0.3500 |
| Bid | 0.3000 |
| Ask | 0.5500 |
| Strike | 17.00 |
| Expiry date | 2023-01-20 |
| Day's range | 0.3500 - 0.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 540 |
- Business Wire
Takeda Delivers Strong FY2021 Results; Continued Growth Momentum Expected in FY2022
OSAKA, Japan, May 11, 2022--Takeda (TOKYO:4502/NYSE:TAK) today announced strong financial results for fiscal year 2021 (period ended March 31, 2022), driven by the performance of its growth products, new product launches and strength across its key business areas.
- Business Wire
Takeda Recognized as the 2022 ISPE Facility of the Year Awards Winner in Two Categories
OSAKA, Japan & CAMBRIDGE, Mass., April 26, 2022--Takeda (TSE:4502/NYSE:TAK) today announced that the International Society for Pharmaceutical Engineering (ISPE) has awarded the company top honors in the Supply Chain and Pharma 4.0™ categories for the 2022 Facility of the Year Awards (FOYA). In the Supply Chain category, Takeda was awarded for its implementation of a new patient-focused supply chain for its allogeneic mesenchymal stem cell therapy; and Takeda’s vaccine production facility in Sing
- Business Wire
Takeda Presents New Exploratory Analysis Showing Patients Treated With LIVTENCITY™ (Maribavir) Had Reductions in Hospitalization Rates and Length of Hospital Stay
OSAKA, Japan & CAMBRIDGE, Mass., April 22, 2022--Takeda (TSE:4502/NYSE:TAK) ("Takeda") today announced that it will present four company-sponsored abstracts at the Tandem Transplantation & Cellular Therapy Meetings in Salt Lake City, Utah, and the 32nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Lisbon, Portugal between April 23 and 26, 2022. The exploratory data presented at both meetings provide an opportunity to share important new analyses of LIVTENCITY™ (m
